Entity

Time filter

Source Type

Washington, DC, United States

Georgetown University is a private research university in Washington, D.C. Founded in 1789, it is the oldest Catholic college or university in the United States, and so the oldest Jesuit university in the country. Georgetown's main campus, located in Washington's Georgetown neighborhood, is noted for Healy Hall, a National Historic Landmark in the Romanesque revival style. Georgetown Law School is located on Capitol Hill and Georgetown has auxiliary campuses in Italy, Turkey, and Qatar.Georgetown's founding by John Carroll, as America's first Catholic bishop, realized earlier efforts to establish a Roman Catholic college in the province of Maryland that had been thwarted by religious persecution. The university expanded after the American Civil War under the leadership of Patrick Francis Healy, who came to be known as Georgetown's "second founder" despite having been born a slave by law. Jesuits have participated in the university's administration since 1805, a heritage Georgetown celebrates, but the university has always been governed independently of the Society of Jesus and of church authorities.The university has about 7,000 undergraduate and over 10,000 post-graduate students from a wide variety of religious, ethnic, and geographic backgrounds, including 130 foreign countries. The university's most notable alumni are prominent in public life in the United States and abroad. Among them are former U.S. President Bill Clinton, U.S. Supreme Court Associate Justice Antonin Scalia, dozens of U.S. governors and members of Congress, heads of state or government of more than a dozen countries, royalty and diplomats.Campus organizations include the country's largest student-run business and largest student-run financial institution. Georgetown's athletic teams, nicknamed the Hoyas, include a men's basketball team that has won a record-tying seven Big East championships, appeared in five Final Fours, and won a national championship in 1984. Wikipedia.


Cheson B.D.,Georgetown University
Journal of Clinical Oncology | Year: 2010

The availability of safe and effective monoclonal antibodies (mAbs) has dramatically altered treatment strategies for B-cell malignancies. Rituximab, a type I chimeric anti-CD20 mAb, not only has activity against a broad range of CD20-positive B-cell malignancies but also, when combined with chemotherapy or other biologic agents, has improved response rates; in addition, in certain situations, progression-free survival and even overall survival may be prolonged. Recently, other anti-CD20 mAbs have been developed to improve on the activity achieved with rituximab or to demonstrate efficacy in patients whose diseases are resistant to rituximab. The most extensively studied of these is ofatumumab, a type I human antibody that binds to a different epitope of CD20 than rituximab. Preclinical data suggest improved complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity compared with rituximab. In early clinical trials, ofatumumab demonstrated single-agent activity against chronic lymphocytic leukemia (CLL) and a number of histologies of B-cell non-Hodgkin's lymphomas. This antibody was recently approved by the US Food and Drug Administration for the treatment of CLL that is resistant to both fludarabine and alemtuzumab. Additional study is ongoing with ofatumumab in combination with chemotherapy and biologic agents to further enhance its efficacy. Ofatumumab offers another effective agent with which to improve the outcome of patients with B-cell malignancies. © 2010 by American Society of Clinical Oncology. Source


Wilcox C.S.,Georgetown University
Pharmacology and Therapeutics | Year: 2010

Tempol is a redox-cycling nitroxide that promotes the metabolism of many reactive oxygen species (ROS) and improves nitric oxide bioavailability. It has been studied extensively in animal models of oxidative stress. Tempol has been shown to preserve mitochondria against oxidative damage and improve tissue oxygenation. Tempol improved insulin responsiveness in models of diabetes mellitus and improved the dyslipidemia, reduced the weight gain and prevented diastolic dysfunction and heart failure in fat-fed models of the metabolic syndrome. Tempol protected many organs, including the heart and brain, from ischemia/reperfusion damage. Tempol prevented podocyte damage, glomerulosclerosis, proteinuria and progressive loss of renal function in models of salt and mineralocorticosteroid excess. It reduced brain or spinal cord damage after ischemia or trauma and exerted a spinal analgesic action. Tempol improved survival in several models of shock. It protected normal cells from radiation while maintaining radiation sensitivity of tumor cells. Its paradoxical pro-oxidant action in tumor cells accounted for a reduction in spontaneous tumor formation. Tempol was effective in some models of neurodegeneration. Thus, tempol has been effective in preventing several of the adverse consequences of oxidative stress and inflammation that underlie radiation damage and many of the diseases associated with aging. Indeed, tempol given from birth prolonged the life span of normal mice. However, presently tempol has been used only in human subjects as a topical agent to prevent radiation-induced alopecia. © 2010 Elsevier Inc. Source


Weiss R.G.,Georgetown University
Journal of the American Chemical Society | Year: 2014

A Perspective is presented on the history and current understanding of molecular gels and the factors that must be considered to characterize them. The abilities of the most important structural, dynamic, and rheological tools available currently to provide the information necessary to follow the formation of a molecular gel from its initial sol phase and then to define it at different distance and time scales are discussed. Approaches to determining a priori when a molecule will gelate a selected liquid, as well as possible methodologies for overcoming current limitations in understanding molecular gels, are presented. Finally, some of the many potential and realized applications for these materials are enumerated. © 2014 American Chemical Society. Source


Becerra S.P.,U.S. National Institutes of Health | Notario V.,Georgetown University
Nature Reviews Cancer | Year: 2013

The potent actions of pigment epithelium-derived factor (PEDF) on tumour-associated cells, and its extracellular localization and secretion, stimulated research on this multifunctional serpin. Such studies have identified several PEDF receptors and downstream signalling pathways. Known cellular PEDF responses have expanded from the initial discovery that PEDF induces retinoblastoma cell differentiation to its anti-angiogenic, antitumorigenic and antimetastatic properties. Although the diversity of PEDF activities seems to be complex, they are consistent with the varied mechanisms that regulate this multimodal factor. If PEDF is to be used for cancer management, a deeper appreciation of its many functions and mechanisms of action is needed. © 2013 Macmillan Publishers Limited. All rights reserved. Source


Gostin L.O.,Georgetown University
JAMA - Journal of the American Medical Association | Year: 2012

Health inequalities represent perhaps the most consequential global health challenge and yet they persist despite increased funding and innovative programs. The United Nations is revising the Millennium Development Goals (MDGs) that will shape the world for many years to come. What would a transformative post-MDG framework for global health justice look like? A global coalition of civil society and academics - the Joint Action and Learning Initiative on National and Global Responsibilities for Health (JALI) - has formed an international campaign to advocate for a Framework Convention on Global Health (FCGH). Recently endorsed by the UN Secretary-General, the FCGH would reimagine global governance for health, offering a new post-MDG vision. This Special Communication describes the key modalities of an FCGH to illustrate how it would improve health and reduce inequalities. The modalities would include defining national responsibilities for the population's health; defining international responsibilities for reliable, sustainable funding; setting global health priorities; coordinating fragmented activities; reshaping global governance for health; and providing strong global health leadership through the World Health Organization. ©2012 American Medical Association. All rights reserved. Source

Discover hidden collaborations